Shares of Cytosorbents Corp (NASDAQ:CTSO) have earned an average rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $10.65.
CTSO has been the topic of several analyst reports. B. Riley reiterated a “buy” rating and set a $11.25 target price on shares of Cytosorbents in a report on Friday, November 10th. ValuEngine upgraded Cytosorbents from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Cytosorbents in a report on Tuesday, January 9th. Finally, Maxim Group set a $12.00 target price on Cytosorbents and gave the stock a “buy” rating in a report on Monday, December 11th.
Cytosorbents (CTSO) traded up $0.45 during mid-day trading on Wednesday, hitting $7.67. The stock had a trading volume of 137,400 shares, compared to its average volume of 143,521. The company has a quick ratio of 3.17, a current ratio of 3.36 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $219.49, a PE ratio of -20.13 and a beta of -0.18. Cytosorbents has a 52 week low of $3.30 and a 52 week high of $7.90.
In other Cytosorbents news, CFO Kathleen P. Bloch sold 12,400 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $7.75, for a total value of $96,100.00. Following the sale, the chief financial officer now owns 241,038 shares in the company, valued at $1,868,044.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Vincent Capponi sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the completion of the sale, the chief operating officer now owns 271,062 shares in the company, valued at approximately $1,897,434. The disclosure for this sale can be found here. Insiders have sold 48,800 shares of company stock worth $360,620 in the last quarter. 5.60% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the business. Fortaleza Asset Management Inc. raised its stake in Cytosorbents by 81.6% in the third quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after buying an additional 10,500 shares during the period. PEAK6 Investments L.P. raised its stake in Cytosorbents by 13.7% in the fourth quarter. PEAK6 Investments L.P. now owns 99,744 shares of the medical research company’s stock valued at $648,000 after buying an additional 12,022 shares during the period. Wells Fargo & Company MN raised its stake in Cytosorbents by 182.3% in the fourth quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock valued at $136,000 after buying an additional 13,515 shares during the period. PNC Financial Services Group Inc. raised its stake in Cytosorbents by 145.2% in the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after buying an additional 22,500 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in Cytosorbents in the fourth quarter valued at approximately $146,000. Hedge funds and other institutional investors own 9.96% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/19/cytosorbents-corp-ctso-receives-10-65-average-pt-from-analysts.html.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.